According to the Zhitong Finance APP, JINYU (600201.SH) announced that it recently received the "Decision on Issuing a Warning Letter to JINYU Biotechnology Co., Ltd. and Related Responsible Personnel" [2025] No. 15 issued by the Inner Mongolia Regulatory Bureau of the China Securities Regulatory Commission.

After investigation, your company has the following violations: 1. Inaccurate accounting for the capitalization of research and development expenses. In 2023, some of the company's R&D projects had not yet reached the capitalization point, and related expenditures were capitalized by being included in the "development expenditures" account. This matter does not comply with Article 8 and Article 9 of the "Accounting Standards for Enterprises No. 6 - Intangible Assets," affecting the accuracy of related financial information and violating Article 3, Paragraph 1 of the "Administrative Measures for Information Disclosure of Listed Companies" (CSRC Order No. 182, hereinafter referred to as the "Information Disclosure Measures"). 2. Inaccurate basis for accounting for long-term equity investments. When accounting for investment income from Guoyi Life Science Technology (Langfang Airport Free Trade Zone) Co., Ltd. and Beijing Jiuyang Wisdom Investment Fund Management Co., Ltd., the company calculated based on the financial statements of the parent company of the invested units. This matter does not comply with Article 11 of the "Accounting Standards for Enterprises No. 2 - Long-term Equity Investments," affecting the accuracy of related financial information and violating Article 3, Paragraph 1 of the "Information Disclosure Measures." 3. Inaccurate disclosure of litigation information. In the 2023 annual report, the company only disclosed the litigation matter with Liaoning Investment Group Co., Ltd. in the "Contingent Matters" section, failing to disclose the fact of losing the first instance. This matter violates the relevant provisions of Article 3, Paragraph 1 of the "Information Disclosure Measures."